Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-439-9100
Debt
Current Ratio12.19
Quick Ratio12.19
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees47
OptionableNot Optionable
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions
What is Kiniksa Pharmaceuticals' stock symbol?
Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."
How were Kiniksa Pharmaceuticals' earnings last quarter?
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) issued its quarterly earnings data on Thursday, November, 1st. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.
When is Kiniksa Pharmaceuticals' next earnings date?
What price target have analysts set for KNSA?
4 analysts have issued 1 year target prices for Kiniksa Pharmaceuticals' shares. Their predictions range from $29.00 to $44.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $35.3333 in the next twelve months. This suggests a possible upside of 54.9% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.
What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.
Has Kiniksa Pharmaceuticals been receiving favorable news coverage?
News stories about KNSA stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a news impact score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Kiniksa Pharmaceuticals' key competitors?
Some companies that are related to Kiniksa Pharmaceuticals include FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Akcea Therapeutics (AKCA) and Ligand Pharmaceuticals (LGND).
Who are Kiniksa Pharmaceuticals' key executives?
Kiniksa Pharmaceuticals' management team includes the folowing people:
- Mr. Sanj K. Patel, CEO & Chairman (Age 48)
- Mr. Stephen Mahoney, Pres & COO (Age 47)
- Dr. John F. Paolini, Chief Medical Officer (Age 53)
- Mr. Chris Heberlig, Chief Financial Officer (Age 43)
- Mr. Thomas W. Beetham, Chief Legal Officer (Age 48)
When did Kiniksa Pharmaceuticals IPO?
(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
When did Kiniksa Pharmaceuticals' lock-up period expire?
Kiniksa Pharmaceuticals' lock-up period expired on Tuesday, November 20th. Kiniksa Pharmaceuticals had issued 8,477,777 shares in its public offering on May 24th. The total size of the offering was $152,599,986 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy shares of Kiniksa Pharmaceuticals?
Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kiniksa Pharmaceuticals' stock price today?
One share of KNSA stock can currently be purchased for approximately $22.81.
How big of a company is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals has a market capitalization of $1.03 billion. Kiniksa Pharmaceuticals employs 47 workers across the globe.
What is Kiniksa Pharmaceuticals' official website?
How can I contact Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]
MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
